All In Biotech

Drug Trial Radar · NCT02318303

To Study GSP 301 in Patients With Seasonal Allergic Rhinitis

A Double-blind, Randomized, Parallel-group, Comparative Study to Evaluate the Efficacy, Safety and Tolerability of Two Different Strengths and Regimens of a Fixed Dose Combination GSP 301 Nasal Spray Compared With Placebo Nasal Spray and Individual Monotherapy Formulations (Comparators), in Subjects (12 Years of Age and Older) With Seasonal Allergic Rhinitis (SAR)

Last checked: Nov 19, 2026Latest source record: Oct 20, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,111 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,111

Actual

Start

Dec 2014

Primary completion

Feb 2015

Study completion Feb 2015

Sponsor

Sponsor type
Industry
First posted
Dec 17, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study to evaluate the two different strengths and dose regimen of GSP 301 to be effective in treatment of seasonal allergic rhinitis.

Conditions

  • Seasonal Allergic Rhinitis

Interventions

  • GSP 301-1 NS (QD)Drug

    GSP 301-1 NS (665 μg olopatadine hydrochloride/50 μg mometasone furoate) administered as 2 sprays/nostril

  • GSP 301-2 NS (BID)Drug

    GSP 301-2 NS (665 μg olopatadine hydrochloride/25 μg mometasone furoate) administered as 2 sprays/nostril

  • GSP 301 Placebo NSDrug

    GSP 301 placebo NS administered as 2 sprays/nostril

  • Olopatadine HCl-1 NS (QD)Drug

    Olopatadine HCl-1 NS (665 μg) administered as 2 sprays/nostril

  • Olopatadine HCl-2 NS (BID)Drug

    Olopatadine HCl-2 NS (665 μg) administered as 2 sprays/nostril

  • Mometasone Furoate-1 NS (QD)Drug

    Mometasone furoate -1 NS (50 μg) administered as 2 sprays/nostril

  • Mometasone Furoate-2 NS (BID)Drug

    Mometasone furoate-2 NS (25 μg) administered as 2 sprays/nostril

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in rTNSS From Baseline to End of TreatmentTime frame: 14 days

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Glenmark Investigational Site 10

    Austin, Texas

  • Glenmark Investigational Site 5

    Austin, Texas

  • Glenmark Investigational Site 6

    Austin, Texas

  • Glenmark Investigational Site 2

    Kerrville, Texas

  • Glenmark Investigational Site 7

    New Braunfels, Texas

  • Glenmark Investigational Site 3

    San Antonio, Texas

  • Glenmark Investigational Site 4

    San Antonio, Texas

  • Glenmark Investigational Site 8

    San Antonio, Texas

  • Glenmark Investigational Site 9

    San Antonio, Texas

  • Glenmark Investigational Site 1

    Waco, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.